Gout Prophylaxis and Treatment

Introduction to Gout Management

The American College of Rheumatology recommends allopurinol as the first-line urate-lowering therapy (ULT) for patients with normal kidney function, started at 100 mg/day and titrated upward every 2-4 weeks to achieve serum uric acid <6 mg/dL 1, 2.
ULT is indicated for all patients with recurrent flares, tophi, urate arthropathy, and/or renal stones 1.
Allopurinol addresses the root cause by lowering serum uric acid levels and should be maintained lifelong 1, 2.

Colchicine (0.5-1 mg/day) is recommended for prophylaxis during the first 6 months of ULT to prevent acute flares triggered by mobilization of urate crystals 1, 2.
Colchicine does not lower uric acid and cannot replace ULT 3, 4, 5.
For treating acute gout flares within 12 hours of onset: colchicine 1 mg loading dose followed by 0.5 mg one hour later 1, 2, 6.

Severe renal impairment (GFR <30 mL/min) is an absolute contraindication for colchicine due to significantly impaired clearance 1, 2, 6.
Concurrent strong P-glycoprotein and/or CYP3A4 inhibitors (cyclosporin, clarithromycin, ketoconazole, ritonavir) are absolute contraindications for colchicine due to fatal toxicity risk 1, 2, 6.
Renal impairment requires a reduced colchicine dose proportionally to creatinine clearance 1, 2.

If colchicine is contraindicated or not tolerated: low-dose NSAIDs with gastroprotection can be used as an alternative 1, 2, 4.
NSAIDs should be avoided in severe renal impairment 1, 2.

Never use colchicine as monotherapy for long-term gout management when ULT is indicated—this fails to address the underlying hyperuricemia 1, 2.
Do not prescribe colchicine with strong CYP3A4/P-gp inhibitors without dose adjustment or alternative therapy 1, 2, 6.
Do not continue colchicine prophylaxis indefinitely—reassess need after 6 months based on flare frequency and uric acid control 1, 2.

The American College of Physicians guidelines recommend continuing colchicine prophylaxis for at least 6 months after starting allopurinol, or until serum uric acid is normalized AND the patient has been free from acute attacks for several months is not included due to lack of proper citation, however, Major clinical trials demonstrated that when prophylaxis was discontinued at 8 weeks, the proportion of patients experiencing acute attacks doubled from 20% to 40%, whereas the trial that continued prophylaxis for the full 6 months showed no spike in attacks 7, 8

Standard prophylactic dose is colchicine 0.5-1 mg daily (not the higher doses used for acute attacks) 9, 10
The lower prophylactic dose causes significantly less diarrhea than higher doses while maintaining efficacy 9

Monitor for neurotoxicity with prolonged colchicine use, particularly in patients with renal impairment 9, 10

If colchicine is contraindicated or not tolerated, use low-dose NSAIDs with gastroprotection as an alternative for the same 6-month duration 9

Never discontinue prophylaxis at 8 weeks despite older practice patterns—this is the exact timepoint when flare risk spikes 7, 8
In patients with greater crystal loads (tophi, chronic tophaceous gout), consider extending prophylaxis beyond 6 months 9

Acute gouty attacks are triggered by rapid reduction in serum uric acid that mobilizes urate crystals during the first months of urate-lowering therapy 9, 10, 11
Evidence shows fewer attacks per patient per month with colchicine co-prescription compared to urate-lowering therapy alone (effect size 0.74, p<0.05) 10, 11